阿尔茨海默氏症中的CRISPR:为神经退行性弹性提供工程遗传解决方案
Roshan Shah1,2, Zheng Tao3, Yuanyuan Wang1
1School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China.
Current neuropharmacology
|January 22, 2026
概括
基因编辑CRISPR提供了一种精确的方法来准阿尔茨海默病 (AD) 的遗传原因. 这种方法纠正了模型中的突变,显示了扭转AD病理和改善治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物技术是生物技术.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,有效治疗方法有限.
- 目前针对粉样β (Aβ) 和的治疗方法在临床试验中表现出有限的成功.
- 遗传因素在阿尔茨海默病变发生过程中发挥着重要作用,为潜在的治疗点提供了治疗点.
研究的目的:
- 审查CRISPR/Cas9基因编辑作为阿尔茨海默病的治疗策略.
- 评估CRISPR/Cas9的潜力,以准阿尔茨海默病的遗传驱动因素和修改疾病病理.
- 讨论在AD治疗中使用CRISPR/Cas9的挑战和未来方向.
主要方法:
- 在AD研究中对CRISPR/Cas9应用的审查.
- 对针对AD相关基因 (例如APP,APOE,PSEN1/2,CD2AP) 的研究进行分析.
- 在诱导多能干细胞 (iPSC) 和有机细胞模型中评估CRISPR/Cas9的疗效.
主要成果:
- 克里斯普尔/卡斯9在破坏病原性阿尔茨海默症等位基因方面表现出精确性.
- 基因编辑纠正iPSC/有机体模型中的突变,使Aβ42/40比率正常化,并减少陶过酸化.
- 临床前研究表明,粉样蛋白积累和突触退化的逆转.
结论:
- 通过解决根源的遗传原因,CRISPR/Cas9对阿尔茨海默病治疗具有变革性的潜力.
- 克服非目标效应和血脑屏障 (BBB) 交付等挑战对于临床翻译至关重要.
- 整合下一代编辑器和改进的交付系统将推进基于CRISPR的AD治疗.
相关概念视频
00:49What is Genetic Engineering?
Overview
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...